Abstract
The p53/p14ARF/mdm2 stress response pathway plays a central role in mediating cellular responses to oncogene activation, genome instability, and therapy-induced DNA damage. Abrogation of the pathway occurs in most if not all cancers, and may be essential for tumor development. The high frequency with which the pathway is disabled in cancer and the fact that the pathway appears to be incompatible with tumor cell growth, has made it an important point of focus in cancer research and therapeutics development. Recently, Nucleophosmin (NPM, B23, NO38 and numatrin), a multifunctional nucleolar protein, has emerged as a p14ARF binding protein and regulator of p53. While complex formation between ARF and NPM retains ARF in the nucleolus and prevents ARF from activating p53, DNA damaging treatments promote a transient subnuclear redistribution of ARF to the nucleoplasm, where it interacts with mdm2 and promotes p53 activation. The results add support to a recently proposed model in which the nucleolus serves as a p53-uspstream sensor of stress, and where ARF links nucleolar stress signals to nucleoplasmic effectors of the stress response. A better understanding of ARF’s nucleolar interactions could further elucidate the regulation of the p53 pathway and suggest new therapeutic approaches to restore p53 function.
Similar content being viewed by others
References
Ayrault O, Andrique L, Larsen CJ, Seite P (2004) Human Arf tumor suppressor specifically interacts with chromatin containing the promoter of rRNA genes. Oncogene 23:8097–8104
Ayrault O, Karayan L, Riou J-F, Larsen C-J, Seite P (2003) Delineation of the domains required for physical and functional interaction of p14ARF with human topoisomerase I. Oncogene 22:1945–1954
Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH (1998) p14ARF links the tumour suppressors RB and p53. Nature 395:124–125
Bertwistle D, Sugimoto M, Sherr CJ (2004) Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 24:985–996
Bischoff FZ, Yim SO, Pathak S, Grant G, Siciliano MJ, Giovanella BC, Strong LC, Tainsky MA (1990) Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. Cancer Res 50:7979–7984
Borel F, Lohez OD, Lacroix FB, Margolis RL (2002) Multiple centrosomes arise from tetraploidy checkpoint failure and mitotic centrosome clusters in p53 and RB pocket protein-compromised cells. Proc Natl Acad Sci USA 99:9819– 9824
Borer RA, Lehner CF, Eppenberger HM, Nigg EA (1989) Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 56:379–390
Brady SN, Yu Y, Maggi LB Jr, Weber JD (2004) ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol Cell Biol 24:9327–9338
Chan HJ, Weng JJ, Yung BY (2005) Nucleophosmin/B23-binding peptide inhibits tumor growth and up-regulates transcriptional activity of p53. Biochem Biophys Res Commun 333:396–403
Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways [see comments]. Nature 362:849–852
Colombo E, Bonetti P, Lazzerini Denchi E, Martinelli P,␣Zamponi R, Marine JC, Helin K, Falini B, Pelicci PG␣(2005) Nucleophosmin is required for DNA integrity␣and p19Arf protein stability. Mol Cell Biol 25:8874–8886
Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG (2002) Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 4:529–533
Culotta V, Sollner-Webb B (1988) Sites of topoisomerase I action on X. laevis ribosomal chromatin: transcriptionally active rDNA has an approximately 200 bp repeating structure. Cell 52:585–597
David-Pfeuty T, Nouvian-Dooghe Y (2002) Human p14(Arf): an exquisite sensor of morphological changes and of short-lived perturbations in cell cycle and in nucleolar function. Oncogene 21:6779–6790
de Rozieres S, Maya R, Oren M, Lozano G (2000) The loss of mdm2 induces p53-mediated apoptosis. Oncogene 19:1691–1697
de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW (1998) E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 12:2434–2442
DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR (1997) Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci USA 94:7245–7250
den Besten W, Kuo ML, Williams RT, Sherr CJ (2005) Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle 4:1593–1598
Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi YP, Pinkel D, Gray J, Bradley A, Medina D, Varmus HE (1995) Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev 9:882–895
Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi YP, Pinkel D, Gray J, Bradley A, Medina D, Varmus HE (1996) The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model. Prog Clin Biol Res 395:1–11
Dorigo O, Turla ST, Lebedeva S, Gjerset RA (1998) Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. J Neurosurg 88:535–540
Dumbar TS, Gentry GA, Olson MO (1989) Interaction of nucleolar phosphoprotein B23 with nucleic acids. Biochemistry 28:9495–9501
Dundr M, Olson MO (1998) Partially processed pre-rRNA is preserved in association with processing components in nucleolus-derived foci during mitosis. Mol Biol Cell 9:2407–2422
Duro D, Bernard O, Della Valle V, Berger R, Larsen CJ (1995) A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 11:21–29
Edelman J, Edelman J, Nemunaitis J (2003) Adenoviral p53 gene therapy in squamous cell cancer of the head and neck region. Curr Opin Mol Ther 5:611–617
Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG, Martelli MF (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254–266
Feuerstein N, Mond JJ (1987a) Identification of a prominent nuclear protein associated with proliferation of normal and malignant B cells. J Immunol 139:1818–1822
Feuerstein N, Mond JJ (1987b) “Numatrin,” a nuclear matrix protein associated with induction of proliferation in B lymphocytes. J Biol Chem 262:11389–11397
Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF (1996) Abnormal centrosome amplification in the absence of p53. Science 271:1744–1747
Gjerset R, Haghighi A, Lebedeva S, Mercola D (2001) Gene therapy approaches to sensitization of human prostate carcinoma to cisplatin by adenoviral expression of p53 and by antisense jun kinase oligonucleotide methods. Methods Mol Biol 175:495–520
Gjerset RA, Bandyopadhyay K (2006) Regulation of P14ARF through subnuclear compartmentalization. Cell Cycle 5:686–690
Gjerset RA, Lebedeva S, Haghighi A, Turla ST, Mercola D (1999) Inhibition of the Jun kinase pathway blocks DNA repair, enhances p53-mediated apoptosis and promotes gene amplification. Cell Growth Differ 10:545–554
Gjerset RA, Mercola D (2000) Sensitization of tumors to chemotherapy through gene therapy. Adv Exp Med Biol 465:273–291
Gjerset RA, Turla ST, Sobol RE, Scalise JJ, Mercola D, Collins H, Hopkins PJ (1995) Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 14:275–285
Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K, Pandolfi PP (2005) Role of nucleophosmin in embryonic development and tumorigenesis. Nature 437:147–153
Grisendi S, Pandolfi PP (2005) NPM mutations in acute myelogenous leukemia. N Engl J Med 352:291–292
Guo QM, Malek RL, Kim S, Chiao C, He M, Ruffy M, Sanka K, Lee NH, Dang CV, Liu ET (2000) Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res 60:5922–5928
Hammond EM, Giaccia AJ (2005) The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun 331:718–725
Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299
Herrera JE, Savkur R, Olson MO (1995) The ribonuclease activity of nucleolar protein B23. Nucleic Acids Res 23:3974–3979
Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorensen B, Montesano R, Harris CC (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3551–3555
Honda R, Yasuda H (1999) Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. Embo J 18:22–27
Hsu CY, Yung BY (1998) Down-regulation of nucleophosmin/B23 during retinoic acid-induced differentiation of human promyelocytic leukemia HL-60 cells. Oncogene 16:915–923
Huang Y, Tyler T, Saadatmandi N, Lee C, Borgstrom P, Gjerset RA (2003) Enhanced tumor suppression by a p14ARF/p53 bicistronic adenovirus through increased p53 protein translation and stability. Cancer Res 63:3646–3653
Iordanov MS, Pribnow D, Magun JL, Dinh TH, Pearson JA, Magun BE (1998) Ultraviolet radiation triggers the ribotoxic stress response in mammalian cells. J Biol Chem 273:15794–15803
Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R, Zhang Y (2003) Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 12:1151–1164
Jayaraman L, Prives C (1999) Covalent and noncovalent modifiers of the p53 protein. Cell Mol Life Sci 55:76–87
Jones SN, Roe AE, Donehower LA, Bradley A (1995) Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206–208
Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440
Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95:8292–8297
Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649– 659
Kapoor M, Lozano G (1998) Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc Natl Acad Sci USA 95:2834–2837
Karayan L, Riou JF, Seite P, Migeon J, Cantereau A, Larsen CJ (2001) Human ARF protein interacts with topoisomerase I and stimulates its activity. Oncogene 20:836–848
Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304–6311
Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587–597
Khan S, Guevara C, Fujii G, Parry D (2004) p14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts. Oncogene 23:6040– 6046
Khan SH, Moritsugu J, Wahl GM (2000) Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proc Natl Acad Sci USA 97:3266–3271
Klein C, Vassilev LT (2004) Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer 91:1415–1419
Kondo T, Minamino N, Nagamura-Inoue T, Matsumoto M, Taniguchi T, Tanaka N (1997) Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Oncogene 15:1275–1281
Korgaonkar C, Hagen J, Tompkins V, Frazier AA, Allamargot C, Quelle FW, Quelle DE (2005) Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol 25:1258–1271
Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299–303
Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ (2004) N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev 18:1862–1874
Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM, Meek D, Laiho M (2004) Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 5:465–475
Lebedeva S, Bagdasarova S, Tyler T, Mu X, Wilson DR, Gjerset RA (2001) Tumor suppression and therapy sensitization of localized and metastatic breast cancer by adenovirus p53. Hum Gene Ther 12:763–772
Lee C, Smith BA, Bandyopadhyay K, Gjerset RA (2005) DNA damage disrupts the p14ARF-B23(nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF. Cancer Res 65:9834–9842
Li J, Zhang X, Sejas DP, Bagby GC, Pang Q (2004) Hypoxia-induced nucleophosmin protects cell death through inhibition of p53. J Biol Chem 279:41275–41279
Li J, Zhang X, Sejas DP, Pang Q (2005) Negative regulation of p53 by nucleophosmin antagonizes stress-induced apoptosis in human normal and malignant hematopoietic cells. Leuk Res 29:1415–1423
Lindstrom MS, Klangby U, Inoue R, Pisa P, Wiman KG, Asker CE (2000) Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus. Exp Cell Res 256:400–410
Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923–935
Llanos S, Clark PA, Rowe J, Peters G (2001) Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol 3:445–452
Lohrum MA, Vousden KH (1999) Regulation and activation of p53 and its family members. Cell Death Differ 6:1162–1168
Lotem J, Sachs L (1993) Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82:1092–1096
Lowe SW, Ruley HE, Jacks T, Housman DE (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957–967
Lu H, Taya Y, Ikeda M, Levine AJ (1998) Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. Proc Natl Acad Sci USA 95:6399–6402
Lu W, Lin J, Chen J (2002) Expression of p14ARF overcomes tumor resistance to p53. Cancer Res 62:1305–1310
Maiguel DA, Jones L, Chakravarty D, Yang C, Carrier F (2004) Nucleophosmin sets a threshold for p53 response to UV radiation. Mol Cell Biol 24:3703–3711
Maltzman W, Czyzyk L (1984) UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4:1689–1694
Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D (1995) A novel p16INK4A transcript. Cancer Res 55:2995–2997
Midgley CA, Desterro JM, Saville MK, Howard S, Sparks A, Hay RT, Lane DP (2000) An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 19:2312–2323
Montes de Oca Luna R, Wagner DS, Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203–206
Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, Look AT (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263:1281–1284
Nozawa Y, Van Belzen N, Van der Made AC, Dinjens WN, Bosman FT (1996) Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol 178:48–52
O’Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285–4300
Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, Knudsen ES, Hofmann IA, Snyder JD, Bove KE, Fukasawa K (2000) Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103:127–140
Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857–860
Olson MO (2004) Sensing cellular stress: another new function for the nucleolus? Sci STKE 2004:pe10
Olson MO, Wallace MO, Herrera AH, Marshall-Carlson L, Hunt RC (1986) Preribosomal ribonucleoprotein particles are a major component of a nucleolar matrix fraction. Biochemistry 25:484–491
Palmero I, Pantoja C, Serrano M (1998) p19ARF links the tumour suppressor p53 to Ras. Nature 395:125–126
Peng Z (2005) Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 16:1016–1027
Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 92:713–723
Prives C (1998) Signaling to p53: breaking the MDM2-p53 circuit. Cell 95:5–8
Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993–1000
Radfar A, Unnikrishnan I, Lee HW, DePinho RA, Rosenberg N (1998) p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. Proc Natl Acad Sci USA 95:13194–13199
Ramsamooj P, Notario V, Dritschilo A (1995) Modification of nucleolar protein B23 after exposure to ionizing radiation. Radiat Res 143:158–164
Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ (1996) The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 87:882–886
Rizos H, Darmanian AP, Holland EA, Mann GJ, Kefford RF (2001) Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF. J Biol Chem 276:41424–41434
Rizos H, Darmanian AP, Mann GJ, Kefford RF (2000) Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization. Oncogene 19:2978–2985
Rubbi CP, Milner J (2003) Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. Embo J 22:6068–6077
Saadatmandi N, Wilson DR, Gjerset RA (2002) p53 gene therapy. In: Encyclopedia of cancer, Vol 3. Academic Press, pp 425–432
Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 12:2831–2841
Savkur RS, Olson MO (1998) Preferential cleavage in pre-ribosomal RNA byprotein B23 endoribonuclease. Nucleic Acids Res 26:4508–4515
Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 [see comments]. Nature 366:704–707
Sherr CJ (2001) The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2:731–737
Sherr CJ (2004) An Arf(GFP/GFP) reporter mouse reveals that the Arf tumor suppressor monitors latent oncogenic signals in vivo. Cell Cycle 3:239–240
Shieh SY, Ikeda M, Taya Y, Prives C (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325–334
Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB (1997) DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11:3471–3481
Stevens C, La Thangue NB (2003) E2F and cell cycle control: a double-edged sword. Arch Biochem Biophys 412:157–169
Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A (1995) Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 55:2988– 2994
Subong EN, Shue MJ, Epstein JI, Briggman JV, Chan PK, Partin AW (1999) Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4–216) recognizes nucleophosmin/B23. Prostate 39:298–304
Sugimoto M, Kuo ML, Roussel MF, Sherr CJ (2003) Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell 11:415–424
Tango Y, Fujiwara T, Itoshima T, Takata Y, Katsuda K, Uno F, Ohtani S, Tani T, Roth JA, Tanaka N (2002) Adenovirus-mediated p14ARF gene transfer cooperates with Ad5CMV-p53 to induce apoptosis in human cancer cells. Hum Gene Ther 13:1373–1382
Tokuyama Y, Horn HF, Kawamura K, Tarapore P, Fukasawa K (2001) Specific phosphorylation of nucleophosmin on Thr(199) by cyclin-dependent kinase 2-cyclin E and its role in centrosome duplication. J Biol Chem 276:21529–21537
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844–848
Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307–310
Wadgaonkar R, Collins T (1999) Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression. J Biol Chem 274:13760–13767
Wang W, Rastinejad F, El-Deiry WS (2003) Restoring p53-dependent tumor suppression. Cancer Biol Ther 2:S55–S63
Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D (1999) Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1:20–26
Wu MH, Chang JH, Yung BY (2002) Resistance to UV-induced cell-killing in nucleophosmin/B23 over-expressed NIH 3T3 fibroblasts: enhancement of DNA repair and up-regulation of PCNA in association with nucleophosmin/B23 over-expression. Carcinogenesis 23:93–100
Wu X, Bayle JH, Olson D, Levine AJ (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7:1126–1132
Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov V, Safiran YJ, Oberoi P, Kenten JH, Phillips AC, Weissman AM, Vousden KH (2005) Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7:547–559
Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM (1992) Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937–948
Yoneda-Kato N, Look AT, Kirstein MN, Valentine MB, Raimondi SC, Cohen KJ, Carroll AJ, Morris SW (1996) The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 12:265–275
Zeller KI, Haggerty TJ, Barrett JF, Guo Q, Wonsey DR, Dang CV (2001) Characterization of nucleophosmin (B23) as a Myc target by scanning chromatin immunoprecipitation. J Biol Chem 276:48285–48291
Zhang R, Wang H, Agrawal S (2005) Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. Curr Cancer Drug Targets 5:43–49
Zhang Y, Xiong Y (1999) Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell 3:579–591
Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725–734
Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12:2424–2433
Zindy F, Williams RT, Baudino TA, Rehg JE, Skapek SX, Cleveland JL, Roussel MF, Sherr CJ (2003) Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci USA 100:15930—15935
Acknowledgements
Our laboratory is supported by the NCI/NIH (CA111868) and the California Tobacco-Related Disease Research Program (11RT-0074). We apologize to the many authors who we were unable to cite due to space limitations.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gjerset, R.A. DNA damage, p14ARF, Nucleophosmin (NPM/B23), and cancer. J Mol Hist 37, 239–251 (2006). https://doi.org/10.1007/s10735-006-9040-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10735-006-9040-y